The global orthopedic soft tissue repair market size was valued at USD 5.9 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.3% from 2021 to 2028. Increasing incidence of soft tissue injuries due to growth in the aging population, obesity rate, sports and physical activity injuries, and trauma accidents is likely to propel market growth over the forecast period. In addition, innovations in new therapies and devices, growing R&D activities, and increasing healthcare awareness and per capita expenditure with a lack of substitutes for soft tissue repair therapies, are other factors expected to drive the demand for orthopedic soft tissue repair therapies. The introduction of new developing technologies, such as biological meshes, bioprinting, and biofabrication, is also expected to bolster market growth. For instance, CoNextions TR by CoNextions Medical provides a fast surgical process, stronger repair strength, and quicker patient recovery as compared to current suture-approach repair procedures.
The surge in the incidence of sports-related injuries along with rapid growth in the number of athletes is key impact-rendering drivers for the market over the forecast period. Sports activities are the leading cause of soft tissue injuries worldwide. Athletes are prone to ACL injuries, which can hinder their mobility. According to an emergency room visits survey conducted by Safe Kids Worldwide, young athletes visit hospital emergency rooms for sports-related injuries more than a million times a year. Rising career opportunities and growing inclination toward fitness, owing to growing health awareness have increased the number of people choosing sports as a hobby or a career. It, in turn, is expected to increase their chances of incurring injuries. For instance, according to the Standard Children’s Health, in the U.S., out of 30 million children and teens participating in sports, about 3.5 million incur injuries.
Improvement of life expectancy has led to an increase in the geriatric population, which is expected to grow significantly in the future. Aging causes critical changes in the skeletal and neuromuscular systems, which may lead to arthritis, weakened ligaments, and ACL tears. An increase in the geriatric population has led to a rise in global demand for orthopedic soft tissue repair surgeries. Currently, the geriatric population is growing rapidly. As per the Population Reference Bureau, in July 2019, the number of Americans aged 65 years, or more is projected to double from an estimated 52 million in 2018 to 95 million by 2060. The overall population aged 65 years and above is anticipated to rise from 16% to 23%. Therefore, the need for acute and long-term healthcare services is increasing, which is expected to drive the market for orthopedic soft tissue repair.
Rising awareness about orthopedic soft tissue repairs is another factor responsible for significant market growth. Neuromuscular training programs are being conducted for athletes, which are expected to significantly help in reducing the risk of ACL tears and other injuries. In addition, increasing awareness about osteoporosis, which is the most common disorder in the population aged over 70 years, is also increasing. As per International Osteoporosis Foundation, the total number of hip fractures is expected to increase from 1.66 million in 1990 to 6.26 million in 2050. The growing prevalence of this disorder can lead to an increase in economic burden for various countries, thereby propelling market growth.
Pandemic Impact |
Post COVID Outlook |
The orthopedic soft tissue repair market decreased by 1.1% from 2019 to 2020 |
The market is estimated to witness a y-o-y growth of approximately 6.7% to 7.1% in the next 5 years |
Factors such as shortage of Personal Protective Equipment (PPE) and trained workforce and restrictions and lockdowns forced the healthcare facilities to reschedule and prioritize procedures as essential or nonessential. During this pandemic, several orthopedic surgeries were considered essential, which can be attributed to the significant market size. |
The healthcare facilities are focused on developing strategies to restart elective orthopedic surgeries once the pandemic stabilizes. Moreover, management of delayed orthopedic-related trauma conditions is a profound task by the evolving healthcare facilities. |
The pandemic affected manufacturing, supply chains, product distribution, operations, and other business activities of the key players. Various companies operating in the market have reported a decline in sales of their orthopedic soft tissue repair products. |
The healthcare facilities are focused on mitigating ley logistical challenges under the guidance of various health care organizations such as WHO, CDC, American college of surgeons. In addition, the orthopedic community is focused on providing the best care for patients in post-acute COVID-19 stages, thereby providing affirmative growth prospects in the coming years. |
Furthermore, increasing investments in R&D, collaborations with other industry players, geographic expansions, and product differentiation are among the key strategies adopted by key companies for gaining a competitive edge in the market. For instance, in December 2020, Zimmer Biomet acquired A&E Medical, a provider of sternal closure devices. This acquisition was expected to strengthen the former’s portfolio of sternal closure products and rigid fixation devices, enabling it to cater to the unmet needs of patients and clinicians.
In 2020, the cruciate ligaments repair segment dominated the market for orthopedic soft tissue repair and accounted for the largest revenue share of 39.8%. The growth is attributed to the increasing incidence of ACL injuries during sporting activities. Soccer and baseball players commonly suffer such types of injury. According to the American Journal of Sports Medicine, the incidence of ACL injury is 68.6/100,000 individuals per year. The increase in the number of sports activities is leading to a rise in the number of sports injuries among athletes, which is further propelling the demand for improved orthopedic soft tissue repair products. As per our estimates in 2018, nearly 399,431 reconstruction procedures were carried out in the U.S., and the number is expected to reach 787,463 by 2025.
This segment is anticipated to register the fastest growth during the forecast period. Injuries to the ACL account for 40% to 50% of all knee ligament injuries. Increasing incidence of knee injuries and the introduction of innovative and technologically advanced products, which are cost-effective and patient-friendly, are among the major factors likely to drive the adoption of these surgeries. Moreover, an increase in awareness about potential threats of developing arthritis from uncorrected ACL tears and injuries is expected to push patients to opt for either invasive or minimally invasive surgeries.
In 2020, the knee application segment dominated the market for orthopedic soft tissue repair and held the largest revenue share of 39.0%. This growth is owing to the greater applicability and acceptability of orthopedic soft tissue repair surgeries and increasing adoption of treatment options in developed and emerging countries. Soft tissue knee injuries are one of the most common musculoskeletal disorders, with the increasing prevalence of knee tissue tears, wear downs or impairments related to sports injuries, age-related issues, trauma, and accidents. In addition, the acceptance and affordability of available treatment options are expected to further drive market growth. In the Global Burden of Diseases (GBD) study of 2017, the impact of musculoskeletal injuries accounted for 16% of all years lived with disability, making it the highest contributor to the global disability index.
However, the hip segment is anticipated to register the fastest growth in the market for orthopedic soft tissue repair during the forecast period. Its rapid growth can be attributed to the increasing incidence of hip joint dysfunction caused by soft tissue injuries. Soft tissue injuries surrounding the hip joint may result in joint dysfunction. Some of the focus areas for hip pathology over the recent years included impingement in the hip and hip labrum tears. With increasing incidences of labral tears, chondral damage, and ligamentum teres lesions of deep soft tissues in the hips, which cannot be corrected or treated effectively with physiotherapy, this segment is gaining attention and driving market players to innovate devices and therapies to provide adequate treatment.
North America dominated the orthopedic soft tissue repair market and accounted for the largest revenue share of 45.7% in 2020 due to the growing number of knee arthroscopies performed in the region. For instance, as per an article published by the Osteoarthritis Research Society International, out of 1 million knee arthroscopies performed annually in the U.S., 700,000 of them involved the meniscus. Another key factor driving the regional growth is attributed to rising healthcare expenditure and investments in healthcare infrastructure as an increase in healthcare spending can help make expensive orthopedic soft tissue repair surgeries more affordable. For instance, according to NHE data demonstrated by KFF, the total national health expenditure of the U.S. increased from USD 3,178 billion in 2015 to USD 3,795 billion in 2019.
However, in Asia Pacific, the market for orthopedic soft tissue repair is anticipated to register the fastest growth during the forecast period owing to the increasing prevalence of musculoskeletal disorders and rising disposable income. Higher penetration of local manufacturers of medical devices is providing significant growth opportunities for the market in the region. Furthermore, the other key factors driving the market are ongoing research in this field, particularly in Japan and India, and the large geriatric population at risk of musculoskeletal disorders. For instance, Japan is considered to be the country with the highest geriatric population in the region.
The market is fragmented in nature, with the presence of a large number of companies. This, in turn, is increasing competition in the market for orthopedic soft tissue repair. Key companies are undergoing the formation of multiple partnerships and MnA to increase their product portfolio, as well as, to expand their footprint across new regions. In addition, companies are focusing on product differentiation and bundling strategies to capture a greater market share. In January 2021, Smith & Nephew acquired the Extremity Orthopedics business from Integra LifeSciences Holdings Corporation for USD 240 million. This acquisition was expected to bolster the extremities segment’s growth, as well as shoulder replacement and foot and ankle segments. Some of the prominent players in the orthopedic soft tissue repair market include:
Arthrex, Inc.
DePuy Synthes, Inc.
Stryker
Wright Medical Group N.V.
Zimmer Biomet
CONMED Corporation
Integra LifeSciences Holding Corporation
Smith & Nephew
Report Attribute |
Details |
Market size value in 2021 |
USD 6.3 billion |
Revenue forecast in 2028 |
USD 9.6 billion |
Growth Rate |
CAGR of 6.3% from 2021 to 2028 |
Base year for estimation |
2020 |
Historical data |
2016 - 2019 |
Forecast period |
2021 - 2028 |
Quantitative units |
Revenue in USD million and CAGR from 2021 to 2028 |
Report coverage |
Revenue, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Application, injury location, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; U.K.; Spain; Italy; France; Russia; Japan; China; India; Australia; South Korea; Singapore; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Arthrex, Inc.; DePuy Synthes, Inc.; Stryker; Wright Medical Group N.V.; Zimmer Biomet; CONMED Corporation; Integra LifeSciences Holding Corporation; Smith & Nephew |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research, Inc. has segmented the global orthopedic soft tissue repair market report on the basis of application, injury location, and region:
Application Outlook (Revenue, USD Million, 2016 - 2028)
Rotator Cuff Repair
Epicondylitis
Achilles Tendinosis Repair
Pelvic Organ Prolapse
Gluteal Tendon Repair
Cruciate Ligaments Repair
Hip Arthroscopy
Biceps Tenodesis
Others
Injury Location Outlook (Revenue, USD Million, 2016 - 2028)
Knee
Shoulder
Hip
Small Joints
Regional Outlook (Revenue, USD Million, 2016 - 2028)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Russia
Asia Pacific
Japan
China
India
Australia
South Korea
Singapore
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
UAE
b. The global orthopedic soft tissue market size was estimated at USD 5.9 billion in 2020 and is expected to reach USD 6.3 billion in 2021.
b. The global orthopedic soft tissue repair market is expected to grow at a compound annual growth rate of 6.3% from 2021 to 2028 to reach USD 9.6 billion by 2028.
b. The cruciate ligaments repair segment dominated the orthopedic soft tissue repair market with a share of 39.8% in 2020.
b. Some key players operating in the orthopedic soft tissue repair market include Stryker, Arthrex, Inc., Zimmer Biomet, DePuy Synthes, Inc, CONMED Corporation, and Smith & Nephew plc.
b. Key factors that are driving the orthopedic soft tissue repair market growth include a rise in the number of sports-related injuries and growth in the aging population, obesity rate, and trauma & accidents.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.